Why I'm Buying Oscar's Panic Dip

Oscar Health (OSCR) shares recently fell 15-20% following Centene's $1.8 billion ACA risk news, despite Oscar reporting robust Q1 fundamentals with 42% revenue growth, 2 million members, and a record-low 15.8% SG&A expense ratio. While analysts like Barclays highlight significant policy risk from potential ACA subsidy expiration, the company's full-stack technology, high retention, and substantial $4.9 billion cash buffer present a potential upside at its 0.46x price-to-sales multiple, even amidst projected H2 membership declines.

Analysis

Oscar Health's stock experienced a significant 15-20% decline, a market reaction triggered by Centene's $1.8 billion ACA risk adjustment disclosure, despite Oscar's own fundamentals remaining strong. The company reported robust 42% revenue growth in Q1, an expansion to 2 million members, and achieved a record-low SG&A expense ratio of 15.8%. However, this operational strength is overshadowed by significant policy risk, as highlighted by a Barclays downgrade, which projects a potential pressure of over 100 basis points on the medical loss ratio (MLR) and aggressive EPS cuts should ACA subsidies expire. The bull case for Oscar rests on its proprietary full-stack technology, including its Campaign Builder AI, which drives high NPS and member retention, creating a competitive advantage legacy insurers may lack. Even with management's guidance for membership declines in the second half of the year, the company's substantial $4.9 billion cash buffer and a low 0.46x price-to-sales multiple suggest a potential valuation disconnect.

Key Decisions for Investors

• Investors should evaluate the recent share price decline as a potential entry point, weighing Oscar's strong Q1 fundamentals against the market's reaction to industry-wide regulatory fears.
• Closely monitor legislative developments regarding the extension of ACA subsidies, as their expiration represents the primary risk factor that could materially impact future profitability and pressure the medical loss ratio.
• The investment thesis depends on whether Oscar's proprietary technology and high retention can successfully offset projected membership declines in H2 and navigate the significant political risks impacting the sector.
• Consider the current 0.46x price-to-sales multiple and the firm's $4.9 billion cash position as key factors that may provide a margin of safety against near-term volatility.